Adaptimmune Reports First Quarter Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Adaptimmune Therapeutics (ADAP) Tops Q1 EPS by 19c
May 12, 2023 7:32 AM EDTAdaptimmune Therapeutics (NASDAQ: ADAP) reported Q1 EPS of $0.00, $0.19 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $47.6 million versus the consensus estimate of $4.9 million.
For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.
... More